Status:

UNKNOWN

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Lead Sponsor:

National Taiwan University Hospital

Conditions:

Overactive Bladder Syndrome

Eligibility:

FEMALE

20+ years

Phase:

PHASE4

Brief Summary

To investigate whether prolonged period of treatment (6 months) can have a better therapeutic outcome than conventional period (3 months) of antimuscarinics.

Detailed Description

Overactive bladder syndrome (OAB), with or without urge incontinence, is characterized by urinary urgency, frequency and nocturia. Thus, patients with OAB could be considered to have a reduced quality...

Eligibility Criteria

Inclusion

  • Women who have overactive bladder syndrome

Exclusion

  • Women who are less than 20 year-old

Key Trial Info

Start Date :

May 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2015

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT01876186

Start Date

May 1 2013

End Date

December 1 2015

Last Update

July 7 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Obstetrics & Gynecology, National Taiwan University Hospital

Taipei, Taiwan, 100

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients | DecenTrialz